Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 outpatients meta-analysis

ACTIV-6
  NCT04885530		 RCTfluvoxamineplaceboCOVID 19 outpatientslow
674/614 inconclusive
  • inconclusive 4 % decrease in recovery (PE) with a high degree of certainty due to low risk of bias
COVID-OUT (fluvoxamine)
  NCT04510194		 RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
334/327 inconclusive
  • inconclusive 6 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias
TOGETHER
  NCT04727424		 RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
741/756 suggested
  • suggested 36 % decrease in clinical deterioration,emergency room observation for > 6 hours or hospitalization (PE) with a moderate degree of certainty due to some concern in risk of bias
Lenze (STOP COVID 1)
  NCT04342663		 RCTfluvoxamineplaceboCOVID 19 outpatientssome concern
80/72 conclusif
  • demonstrated 93 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons